Related Experiment Video
Updated: Aug 5, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Dual targeting of BCL-XL and MCL-1 exposes a rapid and exploitable apoptotic vulnerability in non-small cell lung
Liyang Wu1, Baris Budak1, Oihane Ofogo1
1Institute of Pharmacology, University of Bern, Inselspital, INO-F, Bern, Switzerland.
Abstract:
Non-small cell lung cancer (NSCLC) is frequently refractory to mitochondrial apoptosis despite oncogenic and therapeutic stress. Although individual anti-apoptotic BCL-2 family members have been implicated in NSCLC survival, it has remained unclear whether this reflects dominant single-protein dependencies or a cooperative pro-survival network. This uncertainty is exacerbated by the high prevalence of p53 mutations, which compromise DNA damage-induced apoptotic signaling. Here, we systematically dissected intrinsic apoptotic dependencies across a panel of human NSCLC cell lines using selective BH3 mimetics targeting BCL-2, BCL-XL or MCL-1. Consistent with previous reports, BH3 mimetics alone provided only limited and heterogeneous sensitization to cisplatin across NSCLC models. Likewise, single-agent inhibition of BCL-2, BCL-XL or MCL-1 elicited weak and variable apoptotic responses. In striking contrast, combined targeting of BCL-XL and MCL-1 was sufficient to trigger rapid, synergistic and irreversible apoptosis in the majority of NSCLC cell lines, even in the absence of genotoxic stress. Commitment to cell death occurred within minutes and was characterized by early mitochondrial outer membrane permeabilization, cytochrome c release and robust effector caspase activation. This apoptotic response strictly required the intrinsic mitochondrial machinery and BAX/BAK function but was entirely independent of p53 status. Apparent resistance to first-generation (WEHI-539) BCL-XL inhibition in a subset of models reflected incomplete target engagement rather than compensatory survival rewiring. Accordingly, apoptosis was fully restored by next-generation BCL-XL inhibition (A-1331852) or by PROTAC-mediated BCL-XL degradation (DT2216). Importantly, platelet-sparing BCL-XL targeting strategies retained strong synergy with MCL-1 inhibition, addressing a key translational limitation of earlier BH3-mimetic approaches. Together, these data redefine apoptotic control in NSCLC as a cooperative restraint imposed by BCL-XL and MCL-1 rather than discrete, context-dependent dependencies, revealing a rapid, p53-independent mitochondrial apoptotic vulnerability with clear therapeutic implications.
Insights
Targeting both BCL-XL and MCL-1 simultaneously triggers rapid apoptosis in non-small cell lung cancer (NSCLC) cells. This combined approach overcomes resistance and offers a new therapeutic strategy for NSCLC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Non-small cell lung cancer (NSCLC) often resists apoptosis, hindering treatment efficacy.
- The roles of BCL-2 family proteins in NSCLC survival are complex, especially with frequent p53 mutations.
- Understanding apoptotic dependencies is crucial for developing effective NSCLC therapies.
Purpose of the Study:
- To systematically investigate the intrinsic apoptotic dependencies in NSCLC cell lines.
- To determine if NSCLC survival relies on single anti-apoptotic proteins or a cooperative network.
- To explore novel therapeutic strategies by targeting specific BCL-2 family members.
Main Methods:
- Utilized selective BH3 mimetics to target BCL-2, BCL-XL, and MCL-1 in NSCLC cell lines.
- Assessed sensitization to cisplatin and apoptotic responses to single-agent inhibition.
- Investigated the synergistic effects of combined BCL-XL and MCL-1 inhibition.
- Evaluated the role of p53 status and mitochondrial pathways in apoptosis induction.
Main Results:
- Single-agent inhibition of BCL-2, BCL-XL, or MCL-1 showed limited and variable apoptotic responses in NSCLC.
- Combined targeting of BCL-XL and MCL-1 induced rapid, synergistic, and irreversible apoptosis in most NSCLC cell lines.
- This synergistic apoptosis was p53-independent and relied on the mitochondrial machinery (BAX/BAK).
- Next-generation BCL-XL inhibitors and PROTACs restored apoptosis, addressing target engagement issues.
Conclusions:
- Apoptotic control in NSCLC is primarily driven by a cooperative network of BCL-XL and MCL-1.
- Dual targeting of BCL-XL and MCL-1 represents a potent and p53-independent therapeutic strategy for NSCLC.
- Platelet-sparing BCL-XL inhibitors maintain synergy with MCL-1 inhibition, overcoming translational challenges.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Extrinsic Apoptotic Pathway